Stoke Therapeutics (STOK) announced the presentation of two-year data from the FALCON study, a prospective natural history study in people with Autosomal Dominant Optic Atrophy. Results were presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback